These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 12756822)
1. [The inspection by the Danish Medical Products Agency of drug clinical trials]. Jacobsen E; Stilbo I Ugeskr Laeger; 2003 Apr; 165(16):1656-8. PubMed ID: 12756822 [TBL] [Abstract][Full Text] [Related]
2. [The role of the Danish Medical Products Agency in clinical trials]. Simonsen AC Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821 [TBL] [Abstract][Full Text] [Related]
6. Inspection of clinical investigations by the German health authorities. Schmidt M Methods Find Exp Clin Pharmacol; 1993 May; 15(4):229-31. PubMed ID: 8361260 [TBL] [Abstract][Full Text] [Related]
11. [Public GCP unit--experiences from the Aarhus University Hospital]. Jørgensen A; Rønnow IL; Nexø E Ugeskr Laeger; 2003 Apr; 165(16):1667-9. PubMed ID: 12756826 [TBL] [Abstract][Full Text] [Related]
12. Establishing pan-European clinical trials: regulatory compliance and other practical considerations. Grienenberger A J Biolaw Bus; 2004; 7(4):58-63. PubMed ID: 15675097 [TBL] [Abstract][Full Text] [Related]
13. The impact of escalating regulatory requirements on the conduct of clinical research. Gordon BG; Kessinger A; Mann SL; Prentice ED Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237 [TBL] [Abstract][Full Text] [Related]
14. [Attitude of patient associations to clinical trials of new drugs]. Tybkjaer HW; Witte L; Johannessen MB Ugeskr Laeger; 2003 Apr; 165(16):1688-90. PubMed ID: 12756833 [TBL] [Abstract][Full Text] [Related]
15. Deficiencies in proposed new EU regulation of clinical trials. Gøtzsche PC BMJ; 2012 Dec; 345():e8522. PubMed ID: 23258926 [No Abstract] [Full Text] [Related]
16. [Organization, administration, and performance of clinical studies]. Bachner M; Steininger T; Gneist M Onkologie; 2008; 31 Suppl 2():3-6. PubMed ID: 18487861 [TBL] [Abstract][Full Text] [Related]
17. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase]. Kock M; Thomsen MK Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820 [TBL] [Abstract][Full Text] [Related]